Study of Dextromethorphan in OCD and Related Disorders


I'm Interested

Trial ID: NCT04899687


The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.

Official Title

Fluoxetine/Dextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study

Stanford Investigator(s)

Peter Johannes van Roessel

Clinical Associate Professor, Psychiatry and Behavioral Sciences

Carolyn Rodriguez
Carolyn Rodriguez

Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)


Inclusion Criteria:

* Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)
* Living within California
* Capacity to provide informed consent

Exclusion Criteria:

* Current bipolar disorder or psychotic disorder
* Active moderate or severe substance use disorder, lifetime severe substance use disorder
* Pregnant or nursing women
* Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start
* Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start


drug: Fluoxetine

drug: Dextromethorphan


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Pavithra Makunda, MS